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Abstract
The number of children requiring pediatric intensive care unit (PICU) admission for
severe acute asthma (SAA) around the world has increased.
Objectives:We investigated whether this trend in SAA PICU admissions is present in
the Netherlands.
Methods: A multicenter retrospective cohort study across all tertiary care PICUs in the
Netherlands. Inclusioncriteriawerechildren (2-18years) hospitalized forSAAbetween2003
and 2013. Data included demographic data, asthma diagnosis, treatment, and mortality.
Results: In the 11-year study period 590 children (660 admissions) were admitted to a
PICU with a threefold increase in the number of admissions per year over time. The
severity of SAA seemed unchanged, based on the first blood gas, length of stay and
mortality rate (0.6%). More children received highflow nasal cannula (P < 0.001) and
fewer children needed invasive ventilation (P < 0.001). In 58% of the patients the
maximal intravenous (IV) salbutamol infusion rate during PICU admission was 1mcg/
kg/min. However, the number of patients treated with IV salbutamol in the referring
hospitals increased significantly over time (P = 0.005). The proportion of steroid-naïve
patients increased from 35% to 54% (P = 0.004), with a significant increase in both age
groups (2-4 years [P = 0.026] and 5-17 years [P = 0.036]).
Conclusions: The number of children requiring PICU admission for SAA in the
Netherlands has increased.We speculate that this threefold increase is explained by an
increasing number of steroid-naïve children, in conjunctionwith a lowered threshold for
PICUadmission, possibly causedbyearlier useof salbutamol IV in the referringhospitals.
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1 | INTRODUCTION
Asthma is the most prevalent chronic disease of childhood, with a
prevalence of 5-10% in children up to 12 years in the Netherlands.1,2
Acute asthma exacerbations are a significant burden to patients, their
family and to public health worldwide.
Severe acute asthma (SAA) is defined as an acute asthma
exacerbation that does not respond to conventional therapy with
bronchodilators and systemic corticosteroids. SAA has the poten-
tial to progress to respiratory failure and can be fatal.3 The 2006
national pediatric guideline for SAA in the Netherlands states that
children whose asthma exacerbation does not respond in 30-
60 min to conventional treatment should receive intravenous (IV)
magnesium sulphate (40 mg/kg). The next step is continuous IV
administration of salbutamol followed by immediate transfer to a
pediatric intensive care (PICU), regardless of the dosage of
salbutamol.4
A previous multicenter study on PICU admissions of children with
SAA in the Netherlands showed the following risk factors that were
significantly predictive for PICU admission: active or passive smoking,
allergies, previous hospitalization for asthma, and non-sanitized
homes.5 These risk factors were congruent to studies in other
countries and other populations.6–8 In a recent study in the USA,
treatment with inhaled corticosteroids (ICS) prior to the index
hospitalization was a significant risk factor for ICU admission.9 This
might be due to the fact that children using ICS had more severe
asthma and consequently a higher risk for SAA and PICU admission.
Other relevant risk factors for PICU admission are a shorter duration of
illness before being admitted to the hospital,6 time since asthma
diagnosis8 or viral infections.10
SAA requiring PICU admission represents a major cost burden.
Additionally, PICU admission itself is associated with greater
psychological morbidity in children and their parents, when compared
with admissions in general pediatric wards.11 Unexpected admission of
a child to a PICU is a stressful event and is associated with
posttraumatic stress disorder (PTSD) both in children and their
parents.12,13
Numbers of asthma related PICU admissions have shown a
substantial increase internationally. During a 15-year period in
New Jersey (USA), fewer children with SAA were admitted to a
hospital, but the proportion of patients managed in the PICU
more than tripled.14 A study in Saudi Arabia showed a fourfold
increase of PICU admissions due to SAA in children in 2013
compared to a previous cohort in 2003.15 In the last decade, a
substantial increase in the number of children with SAA admitted
to the PICU of the Erasmus MC-Sophia was observed. To see
whether this was a local or national trend we embarked on a
nationwide study.
The aim of the present study was to examine the trend in
prevalence of PICUadmissions of childrenwith SAA in theNetherlands
and to assess patient characteristics and asthma treatment in the last
decade.
2 | METHODS
2.1 | Inclusion criteria
We conducted a retrospective cohort study of children with SAA,
admitted to the eight PICUs in the Netherlands. These PICUs are part
of university, tertiary hospitals. Children were identified through the
Pediatric Intensive Care Evaluation (PICE) database, a national
database containing all children admitted to Dutch PICUs.
All children aged 2-18 years admitted to one of the eight PICUs
with SAA from January 2003 to December 2013 were eligible for this
study. The SAA diagnosis had to be confirmed before PICU discharge.
Children <2 years of age, who are admitted at the PICU because of
dyspnea generally have respiratory tract infections. In children below
the age of 2 years no firm diagnosis of asthma could be made at the
time of PICU discharge.16,17 All admissions and re-admissions were
included in the study. Because of the retrospective design of the study,
the Medical Ethics Committee waived the need for informed consent.
2.2 | Methods
We identified our patients from the PICE database.18 The PICE registry
was established in 2000 as an independent national nonprofit
foundation to develop and maintain a continuous registration of
data relating to all children admitted to all PICUs in the Netherlands.
The database contains anonymous information regarding character-
istics of patients and admission, severity of illness and risk of mortality,
treatment, and patient outcome.18
Two investigators retrieved all data from electronic patient
records and paper chart review by using an electronic case report
form created in Open Clinica. Data included demographic data, asthma
diagnosis at time of admission, allergies, prescribed asthma treatment
at home, SAA treatment at the referring hospital and PICU, and PICU
mortality.
Inhaled or food allergies were defined as a positive radioallergo-
sorbent test (RAST) or skin prick test, and/or reported by the treating
physician or parents. Prescribed home asthma treatmentwas recorded
if prescribed at least 7 days before the SAA and was categorized
according to the global initiative for asthma (GINA).17
We used the following parameters to assess SAA severity: first pH
and PCO2 obtained at PICU admission, length of stay (LOS) on a PICU,
highest infusion rate of salbutamol IV, and PICU mortality. If missing
data for describing SAA severity exceeded 20%, variables were
excluded from the analyses.
2.3 | Analyses
Data were presented as mean (and standard deviation [SD]) or as
median and interquartile range (IQR) if data were not normally
distributed. To assess changes in treatment over the 11-year study
period, the linear-by-linear chi-square association was used for
dichotomous variables, including magnesium sulphate (MgSO4) and
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IV salbutamol use, invasive mechanical ventilation, and use of inhaled
steroids. Outcomes and patient characteristics were compared
between intubated and non-intubated children, between children
with and without IV salbutamol and between age groups using the
Student's t test for normally distributed variables, the Mann-
Whitney U test for continuous variables that were not normally
distributed and the Pearson chi-square for categorical variables. The
Jonckheere-Terpstra test was used to determine whether the
distribution of continuous variables changed with the year of
admission. Continuous variables included pH and PCO2 at PICU
admission, LOS and highest infusion rate of salbutamol. All statistical
analyses were carried out in SPSS version 21 (Chicago, IL), and a two-
sided significance level of 0.05 was used.
3 | RESULTS
We included 590 eligible children, with a total of 660 PICU admissions.
Baseline and PICU characteristics are described in Tables 1 and 2.
The number of SAA admissions per year on the PICU increased
gradually over the years, from 44 children in 2003 to 138 in 2013
(Figure 1). In this same period the prevalence of asthma in children 2-
18 years of age remained stable.19,20 Reliable data of total asthma
admissions in this age group in the Netherlandswere not available. The
total number of PICU admissions increased by 38% (from4277 in 2003
to 5897 in 2013) (Figure 1). However, the number of SAA PICU
admissions accounts only for a small increase (from 1.0% to 2.3%) of
total PICU admissions. The number of PICUs remained unchanged and
PICU beds increased from 107 to 109 in the Netherlands over time.
The median pH and PCO2 at PICU admission showed an increase and
decrease over time, respectively. Therewas no significant difference in
LOS on the PICU (P = 0.637) or highest infusion rate of salbutamol
(P = 0.712, Table 3). The number of patients treated with MgSO4 and
TABLE 1 Baseline characteristics
Baseline characteristics (n, %)
Sexa
Female 233 (40)
Male 357 (60)
Age
2-4 years 278 (42)
5-18 years 380 (58)
Ethnicitya
White 351 (64)
Non-white 195 (36)
Medication step (GINA)
Step 1 169 (26)
Step 2 196 (31)
Step 3 76 (12)
Step 4 41 (6)
Step 5 9 (1)
No medication 149 (23)
Allergya 284 (50)
Type of allergy if allergic
Inhalation allergies 164 (61)
Food allergies 45 (17)
Both 62 (23)
Diagnosed with asthma prior to PICU admission 501 (77)
Earlier PICU admission for SAA 75 (12)
Earlier NON-PICU admission for SAA 248 (40)
aFor the patient specific characteristics the re-admissions were excluded,
so for sex, ethnicity, and allergy N = 590.
TABLE 2 PICU characteristics
Admission characteristics
pH at admission PICUa 7.37 (7.31-7.41)
PCO2 at admission PICU, kPa
a 5.0 (4.4-6.1)
Length of PICU stay in daysa 3 (2-4)
MgSO4 IV before admission PICU
b 429 (65)
Salbutamol IV before PICU admissionb 351 (54)
Salbutamol IV during PICU admissionb 544 (83)
Duration salbutamol IVb
0-6 h 23 (4)
6-12 h 50 (10)
12-24 h 101 (19)
24-48 h 168 (32)
>48 h 179 (34)
Max. dosage salbutamol IV, mcg/kg/mina 1.0 (0.4-2.0)
Invasive mechanical ventilationb 118 (19)
Mortalityb 4 (0.6)
aMedian (IQR).
bNumber (%).
FIGURE 1 PICU admissions
BOESCHOTEN ET AL.. | 3
IV salbutamol in the referring hospital increased significantly over time
(Table 4).
Over the years the proportion of steroid-naïve patients increased
significantly (P = 0.004) (Table 4). The proportion of patients with a
diagnosis of asthma prior to admission remained stable over the years
(P = 0.086). In 118 admissions (19%) invasive mechanical ventilation was
necessary due to cardiopulmonary resuscitation, secure airway and
breathing for inter-hospital transport to the PICU and/or progressive
respiratory failure (eg, hypoxemia, hypercapnia, apnea). The majority of
the intubated patients received a dosage IV salbutamol of >1mcg/kg/min
and for >24 h during PICU admission. Intubated children had a
significantly longer PICU LOS, lower pH and a higher PCO2 at time of
PICU admission than children not intubated. The proportion of steroid-
naïve children was similar in the intubated and non-intubated group
(Table 5). Over the years there was a statistically significant decreasing
trendofpercentageofmechanicallyventilatedchildren, from24%in2003
to 11% in 2013 (P < 0.001). High-flow nasal cannula was introduced in
2010, and showed an increase in the following years (Table 6).
During PICU admission 83%of the patients received IV salbutamol
(Table 2). Of these patients, 33% received a highest infusion rate of
0.5 mcg/kg/min and 58% a highest infusion rate of 1.0 mcg/kg/min
(Table 7). Seventeen percent (109 children) did not receive IV
salbutamol during PICU admission. PICU LOS was significantly shorter
in the group without IV salbutamol and more children were invasively
mechanically ventilated. Other potential risk factors for IV salbutamol
were not significant (Table 8).
Seven patients (1.1%) needed extracorporeal membrane oxygen-
ation (ECMO). One patient was supported with venoarterial (VA)-
ECMO after extracorporeal cardiopulmonary resuscitation (eCPR).
This patient died during PICU admission (brain death). The others were
supported with venovenous (VV)-ECMO, four due to refractory
hypoxemia and two due to massive air leak syndrome.
Four patients died (0.6%) during the 11-year study period. Two of
these patients were declared brain death following resuscitation. One
patient died of respiratory failure and one of circulatory failure. All four
experienced a cardiac arrest (n = 2 out-of-hospital, n = 1 in a general
hospital, and n = 1 at the PICU). All fatalitieswere non-whitemales, had
doctor-diagnosed asthma andwere prescribed ICS. Three were known
with allergies, of whom two also had a food allergy.
Two different age groups (2-4 years and 5-17 years) were
analyzed separately (Figure 2). The number of children with food or
inhalation allergy, a prior diagnosis of asthma, ICS treatment before
PICU admission and a viral etiology were significantly different
between the two age groups. The proportion of boys, the median pH
and PCO2 at time of PICU admission did not significantly differ
between both age group.
4 | DISCUSSION
During the 11-year study period the number of children aged 2–18
years with SAA admitted to PICUs in the Netherlands increased
threefold. In this same period the prevalence of asthma in this age T
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TABLE 4 Treatment per year
Year of admission 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 P-value for trend
MgSO4
a 28 16 29 37 47 65 67 72 80 86 94 <0.001
Salbutamol IVa 46 46 52 59 43 54 46 40 58 59 66 0.005
MgSO4 PICU 18 22 32 17 25 37 39 35 36 18 16 0.230
Salbutamol IV PICU 80 93 77 94 75 78 72 77 87 85 91 0.080
Steroid-naïve 35 41 43 44 57 47 41 47 55 59 54 0.004
Numbers are presented as percentages per year.
aMgSO4 and salbutamol IV given in the referring hospital (at the pediatric ward or ED).
Non-significant values are presented in bold.
TABLE 5 Invasive mechanical ventilation
Intubated children (N = 118) Non-intubated children (N = 542) P-value
Age in yearsa 5 (3-9) 5 (3-9) 0.164
Maleb 79 (67) 311 (57) 0.047
First SAAb 103 (87) 487 (90) 0.354
Earlier PICU admission for SAAb 17 (15) 58 (11) 0.243
Steroid-naïve before admissionb 52 (46) 267 (51) 0.329
Diagnosed with asthma prior to PICU admissionb 89 (76) 412 (77) 0.769
LOS PICU, daysa 5 (3-7) 3 (2-4) <0.001
pH at PICU admissionc 7.22 (0.14) 7.37 (0.07) <0.001
PCO2 at PICU admission, kPa
c 8.56 (3.85) 5.10 (1.41) <0.001
IV salbutamol during PICU admissionb 109 (92) 435 (81) 0.004
IV salbutamol >24 hb 84 (83) 263 (53) <0.001
IV salbutamol >48 hb 67 (57) 112 (27) <0.001
IV salbutamol >1mcg/kg/minb 69 (66) 196 (46) <0.001
Max. dosage IV salbutamol, mcg/kg/mina 1.6 (0.7-3.4) 0.8 (0.4–2.0) 0.003
aMedian (IQR).
bNumber (%).
cMean (SD).
Non-significant values are presented in bold.
TABLE 6 Respiratory support per year
Year of admission 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
P-value for
trend
None 9 4 4 6 0 4 4 2 0 1 1 0.004
Nasal cannula 20 23 24 14 14 10 14 19 18 17 15 0.461
NRMa 46 27 45 61 72 54 52 57 53 58 53 0.177
HFNCb 0 0 0 0 0 0 0 2 10 13 17 <0.001
NIVc 0 0 0 4 0 2 2 3 0 1 2 0.308
Invasive mechanical
ventilation
24 46 28 14 14 31 27 17 19 10 11 < 0.001
Numbers are presented as percentages per year.
aNon-rebreathing mask.
bHigh-flow nasal cannula.
cNon-invasive ventilation.
Non-significant values are presented in bold.
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group remained stable,19,20 and the number of PICU beds increased
only marginally. The total number of PICU admissions increased by
38%, of which the number of SAA PICU admissions accounted for a
rise from 1.0 to 2.3% of total admissions. The duration of PICU
admission, PICUmortality, first blood gas pH and PCO2 did not change
over time, suggesting similar severity of SAA. Children aged 5-17 years
were more likely to have an allergy, used more ICS before PICU
admission and were more frequently diagnosed with asthma prior to
PICU admission. A viral infection as most likely cause for SAA was
recorded more frequently in children aged 2-4 years. Over the years
significantly more children received MgSO4 and salbutamol IV already
in the referring hospital before being transported to the PICU. We
observed a decrease of invasive mechanical ventilation over time
together with an increased use of high-flow nasal cannulas. Intubated
children had a significantly longer PICU LOS, lower pH and a higher
PCO2 at time of PICU admission than children not intubated. The vast
majority of the intubated patients received a dosage IV salbutamol of
>1mcg/kg/min and for >24 h during PICU admission. Overall, the
highest infusion rate of IV salbutamol was relatively low, with 58%
receiving amaximumdosage of 1.0 mcg/kg/min. Seventeen percent of
the children did not receive IV salbutamol. In these children the PICU
LOS was shorter and fewer children needed invasive mechanically
ventilation.
Our findings are partly consistent with previous studies. Single
center retrospective studies done in Saudi Arabia (2003-2013) and
Taiwan (1990-2000) also showed a significant increase in the number
of children with SAA who required PICU admission, with a fivefold,
respectively, twofold increase.15,21 The authors suggested a lower
threshold for PICU admission over time as a contributing factor to the
increase in PICU admissions as well as implementation of a National
Health insurance (Taiwan). One North-American study described a
threefold increase in PICU admissions, without an increase in illness
severity over time, comparablewith our results.14 That study describes
the hospitalization characteristics of 28.309 children with SAA in
hospitals with and without PICUs in the period 1992-2006. However,
TABLE 7 Maximum dosage of salbutamol IV
Maximal dosage of salbutamol IV in mcg/kg/min N %
0-0.5 176 33
0.6-1.0 130 25
1.1-1.5 46 9
1.6-2.0 52 10
2.1-3.0 40 8
3.1-4.0 30 6
4.1-5.0 22 4
5.1-7.0 14 3
7.1-10.0 19 4
TABLE 8 IV salbutamol
IV salbutamol group (N = 544) Non IV salbutamol group (N = 109) P-value
Age in yearsa 5 (3-9) 5 (3-8) 0.198
Maleb 323 (59) 64 (59) 0.898
First SAAb 488 (90) 99 (91) 0.723
Earlier PICU admission for SAAb 63 (12) 10 (9) 0.459
Steroid-naïve before admissionb 262 (48) 56 (52) 0.560
Diagnosed with asthma prior to PICU admissionb 421 (77) 78 (72) 0.120
LOS PICU, daysa 3 (3-4) 2 (2-3) <0.001
pH at PICU admissionc 7.33 (0.11) 7.38 (0.06) <0.001
PCO2 at PICU admission, kPa
c 5.8 (2.63) 5.1 (1.05) <0.001
Invasive mechanical ventilationb 109 (20) 9 (9) 0.004
aMedian (IQR).
bNumber (%).
cMean (SD).
Non-significant values are presented in bold.
FIGURE 2 Preschoolers versus school-aged children
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in this North-American study, 20% of patients was younger than
2 years of age and comorbidities were not an exclusion criterium. The
results of this heterogeneous study group cannot be compared to our
study, given the difficulty in correctly diagnosing severe wheeze or
asthma in that age group such as excluding bronchiolitis and viral lower
airway infections. Of the patients admitted to a PICU in that study,
10% received mechanical ventilation, with no decrease over time
compared to a decrease of 25-31 to 11% over time in our study. In that
population, the length of stay at the PICU and the mortality rate also
remained stable during this 15-year period.14 Ours and other studies
show higher rates of ICU admission without a change in invasive
mechanical ventilation. This might have been the result of increased
monitoring and available therapies in the PICUs, that prevent
deterioration and the subsequent need for mechanical ventilation
and high-flow oxygen. Two other retrospective studies in Saudi Arabia
(1994-2001, n = 56) and in North-America (2000-2007, n = 222) did
not show an increase in children admitted with SAA on a PICU. Both
were small single center studies.22,23
PICU mortality in children with SAA in the Netherlands is
extremely low. In other countries the (in-hospital) mortality rates
varied between 0.02% and 4%. In a study in the US between 2000
and 2009, the in-hospital mortality of children with SAA decreased
significantly between 2000 and 2009 (0.06% in 2000 vs 0.02% in
2009).24 But in another North-American study25 of 261 high risk
pediatric admissions with fatal and near-fatal asthma admitted to the
PICU as many as 4% died (11 patients). A recent report from New
South Wales in 2015 analyzed all deaths from children with asthma
between 2004 and 2013.26 In New South Wales asthma prevalence
in children is comparable with the Netherlands and a total of 20
deaths occurred in children aged 4-17 years, with a male
predominance (70%). Most of the children (80%) were at home
when they were recognized to be symptomatic with asthma during
their ultimately fatal attack.26
Strengths of the present study include the participation of all
Dutch PICUs and the existence of a national PICU database.
Approximately 5.500 patients are admitted to these PICUs each
year. Furthermore, there is a national guideline for the treatment of
SAA with practical treatment steps and referral guidelines, which
facilitates comparison between PICUs.
There are some limitations as well. The retrospective design of this
study is a disadvantage, but in this case the prospective, structured
registration in a national database should overcome many disadvan-
tages of retrospective data collection. Secondly, our study lacked a
control group. Therefore we could not analyze possible changes in risk
factors for PICU admission like medication adherence, exposure to
cigarette smoke, air pollution and specific seasonal viruses, as these
data were insufficiently available. To identify possible risk factors for
PICU admission, a prospective study comparing children admitted at
PICUs and children admitted at general pediatric wards would be
helpful. Finally, no validated clinical asthma score was systematically
used by all PICUs.
What is the clinical relevance of the present findings? An
increased frequency or severity of illness is not a likely cause of the
threefold increase in PICU admissions, as the prevalence of asthma
in children has remained stable in the Netherlands over these
years,27,28 and the first blood gas pH and PCO2, duration of PICU
admission and PICU mortality did not change over time. The
number of PICU beds in the Netherlands increased by 1.9% and
total PICU admissions increased with 38%, whereas the number of
SAA PICU admissions increased disproportionately with a factor 3.
As we have no evidence to suggest that SAA severity increased,
this may indicate a lower threshold for a PICU admission over time.
A possible explanation is that IV salbutamol has been administered
sooner in the treatment work-up in the referring hospitals over the
years. Our national SAA guideline automatically implies immediate
referral to a PICU, regardless of IV salbutamol dosage. This
recommendation should perhaps be reconsidered in the light of our
findings.
A striking and unexpected observation was themarked increase in
steroid-naïve children that were admitted with SAA over the years.
The interpretation of this finding may simply reflect a first asthmatic
attack of a child not previously diagnosed having asthma. As the
increase was in all age groups this might also indicate a significant
increase of undertreatment of known asthma. Over the 11-year study
period the proportion of children with no previous diagnosis of asthma
remained the same. In a previous study,5 we observed that about one
third of children with SAA admitted to a PICU was not known with
asthma prior to that admission. Studies in Taiwan and Saudi Arabia also
showed a significant number of patients not using daily ICS prior to
PICU admission, respectively, 20% and 46%, compared to 50% in our
study.21,22
Non-invasive respiratory support with external positive end-
expiratory pressure (PEEP) can relieve airway obstruction in children
with asthma,29 and we observed a significant decrease of invasive
mechanical ventilation together with an increased use of high-flow
nasal cannulas. The decreased need for invasivemechanical ventilation
could therefore have resulted from the upcoming use of high-flow
nasal cannula and non-invasive mechanical ventilation, or from earlier
and more frequent administration of MgSO4 and IV salbutamol in the
referring hospitals over the years.
In our cohort, 10-20% of the patients did not receive any
salbutamol infusion during PICU stay. Therefore, one could argue
whether these children really met PICU admission criteria. It is likely
that the referring clinician transferred these children to the PICU
because of potential respiratory failure despite continuous nebuli-
zation and MgSO4 IV, according to the Dutch guideline.
In our study PICU mortality was 0.6%. All fatalities experienced
a cardiac arrest, three of them outside of a PICU. Hence, the
prevention, recognition and management of SAA at home, by
general practitioners and in a regional hospital is very important.
This also emphasizes the importance of proper maintenance
treatment in children with asthma. Because of the already low
mortality, it is not likely that more aggressive therapies will further
reduce mortality.
Our national SAA guideline automatically implies immediate
referral to a PICU, regardless of IV salbutamol dosage. This
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recommendation should perhaps be reconsidered in the light of our
findings. The high costs of PICU admission, bed availability but also
risk of PTSD after PICU admission in children and their parents12,13
are drawbacks of the present development toward more frequent
PICU admission. It is therefore important to reduce unnecessary
PICU admissions. Priority should be given to adequate diagnosis
and anti- inflammatory treatment (preventing undertreatment) of
children with asthma to prevent PICU admissions, to perform
prospective studies into the safety of low dosage IV salbutamol,
and to increase alertness of risk factors for severe SAA.
5 | CONCLUSION
During the last decade we observed an important, threefold increase
in children with SAA admitted to a PICU in the Netherlands, while
the severity of illness remained similar. Most likely reasons are
earlier referral by physicians as a result of better education and
implementation of national SAA guidelines and, possibly, under-
treatment with ICS in children with asthma, missed diagnosis or
underreporting of asthma symptoms. Our results suggest that
aggressive therapy in the referring hospitals and timely referral
could lead to better outcomes of SAA, and prevent deterioration and
need for mechanical ventilation. On the other hand, the high costs of
PICU admission and the risk of PTSD after PICU admission in
children and their parents are drawbacks of the present develop-
ment toward more frequent PICU admission. It is therefore
important to reduce the number of PICU admissions by establishing
proper diagnosis and adequate treatment of children with asthma to
prevent PICU admissions, performing prospective studies into the
safety of salbutamol infusion, and recognizing the children most at
risk for developing SAA.
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